3-MeO-PCP

3-MeO-PCP in a pill form

3-Methoxyphencyclidine (3-MeO-PCP) is a dissociative anesthetic drug that is sold online as a research chemical. The effects are often described as being more euphoric and mentally clearer than many related compounds.

History

A 1965 article published by Maddox described the synthesis of 2-MeO-PCP and 4-MeO-PCP. Preparation of 3-MeO-PCP was described later in 1979 by Geneste et al.

The compound was first synthesized in 1979 to investigate the structure-activity relationship of phencyclidine derivatives. The activity of 3-MeO-PCP in man was not described until 1999 when a chemist using the pseudonym John Q. Beagle wrote that 3-MeO-PCP was qualitatively similar to PCP with comparable potency.

Dosage

3-MeO-PCP, like PCP is active in the single milligram range and therefor can be hard to accurately measure.

Most if not all consumer-grade jewelry-scales advertised as working at the 0.001g (mg) range are not reliably accurate enough to measure quantities weighing less than around 15-25 mg depending on the model and calibration. With a drug as potent as 3-MeO-PCP a small discrepancy in measurement can make a world of difference in physical and mental response to the dose. It is for these reasons that it would be in one's best interest to use a volumetric dose measurement technique as outlined in this guide.

Oral

Threshold	1.5-3 mg
Light	3-5 mg
Common	5-10 mg
Strong	10-15 mg
Heavy	15-18 mg+

Insufflated

Threshold	1-2 mg
Light	2-5 mg
Common	5-8 mg
Strong	8-12 mg
Heavy	12-15 mg+

Duration

Oral

Onset	20-40 minutes
Total	3-5 hours +/- 60 minutes, dependent on dose.
After-effects	2-48 hours

Insufflated

Onset	10-30 minutes
Total	2-4 hours +/- ~30 minutes, dependent on dose.
After-effects	2-48 hours

Effects

Positive

• Increase in energy / stimulation

• Euphoria

• Pleasant mental and/or body high

• Music appreciation

• Disconnected thoughts

• Sense of calm

• Increased sociability, loss of inhibitions

• Closed and open-eye visuals

• Shifts in perception of reality

Neutral

• Increased heart rate (lower doses)

• Altered time perception

• Disrupted speech patterns

• Analgesia (decreased pain awareness) and numbness

• Distorted sensory perceptions, hallucinations

• Unusual and unpredictable behavior

• Mild to moderate dissociation

• Confusion, disorientation

Negative

• Disturbing hallucinations and/or delusions

• Anxiety, paranoia

• Severe dissociation, depersonalization

• Ataxia (loss of motor coordination)

• Psychotic episodes

• Nausea, vomiting

• Temporary amnesia

• Severe distortion or loss of auditory/visual perception

Harm Reduction

• 3-Meo-PCP is a very powerful NMDA antagonist (doses are on par with PCP), and as such it has the potential to be very confusing.
• 3-MeO-PCP is considered to be a 'research-chemical', simply meaning that there is little to no clinical data on long-term effects.
• 3-MeO-PCP, as with all arylcyclohexylamine class dissociative compounds may cause neurotoxicity when used frequently or in high dose.
• 3-MeO-PCP acts as a mild Serotonin Reuptake Inhibitor and as such may risk adverse effects as a result of synergy when used with certain serotogenic drugs or medications. See Interactions.
• It is difficult to measure 3-MeO-PCP accurately with a scale because it is active in the 1-10 mg range. See the dosage section for more information.
• 3-MeO-PCP has a steep dose-response-curve and an onset ranging from approximately 20-40 minutes. It is inadvisable to redose, especially within the first hour.

For more information see Dissociative Harm-Reduction.

Interactions

Check out our Drug Combinations page and chart for interactions and combinations of common drugs. PCP and 3-MeO-PCP have similar profiles and as such its safe to assume the PCP combination-chart data also applies to 3-MeO-PCP.

Specifically, do not mix 3-MeO-PCP with alcohol or benzodiazepines. 3-MeO-PCP will also likely produce synergistic effects if used in conjunction with certain serotogenic medications or drugs.

Chemistry and Pharmacology

3-MeO-PCP binds to the NMDA receptor with higher affinity than PCP and has the highest affinity of the three isomeric anisyl-substitutions, followed by 2-MeO-PCP and 4-MeO-PCP. It is also a Serotonin Reuptake Inhibitor (SRI).

3-MeO-PCP hydrochloride is a white crystalline solid with a melting point of 204-205°C.

3-MeO-PCP has a Ki of 20 nM for the NMDA receptor, 216 nM for the serotonin transporter and 42 for the sigma1 receptor.

Legal status

UK: Class B, as are all arylcyclohexamines.

US: Covered by the analogue act if sold for human consumption.

Links

Wikipedia

Interview with a Ketamine Chemist

From MXE to PCP